Arpida

Arpida Provides Comprhensive Overview of Pivotal Phase III Trial Data

...icated Skin and Skin Structure Infections (cSSSI), arpida Ltd. (SWX: ARPN) today provides a table with the k...results and on those of other studies carried out, arpida is confident that intravenous iclaprim has compell... properties, both in terms of efficacy and safety. arpida has filed a New Drug Application with the US FDA f...

Arpida in Medical Technology

Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome

...Switzerland, November 20 /PRNewswire-FirstCall/ -- arpida (SWX: ARPN) announced today that the Anti-infectiv...in-resistant Staphylococcus aureus (MRSA). arpida remains confident in the efficacy and safety of in...hogens, with a well tolerated side-effect profile. arpida is fully committed to iclaprim's development and w...

Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections

...CH, Switzerland, Oct. 26 /PRNewswire-FirstCall/ -- arpida (SWX: ARPN) today presented the combined results f...han four decades of clinical use. In March 2008, arpida completed the U.S. filing of the New Drug Applicat...FA) goal date of January 16, 2009. In August 2008, arpida announced acceptance of its Marketing Authorizatio...

Arpida Announces Review of Iclaprim NDA by FDA Advisory Committee in November 2008

... Switzerland, October 14 /PRNewswire-FirstCall/ -- arpida Ltd. (SWX: ARPN) today announced that it has recei...an extended range of important pathogens. To date, arpida has filed marketing applications for intravenous i...n Union. Dr Paul Hadvary, Head of Development of arpida Ltd., commented: "We are delighted to have an oppo...

Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

...ability. Dr Paul Hadvary, Head of Development of arpida Ltd., commented: "The speed of enrolment in this P...nd subsequently determine the path ahead." About arpida Ltd. arpida (SWX: ARPN) is a biopharmaceutical company headqua...

Arpida Enrols First Patients in "Intravenous-to-Oral" Switch Trial With Oral Iclaprim

...ACH, Switzerland, May 26 /PRNewswire-FirstCall/ -- arpida Ltd (SWX: ARPN) today announced the enrolment of t...s study. Dr Paul Hadvary, Head of Development of arpida Ltd., commented: "Among the hospital anti-MRSA dru...potential to the intravenous formulation." About arpida Ltd. ...

Arpida Provides Further Comments on the Pivotal Phase III Trials

...Further to the press release published on 9 April, arpida Ltd. (SWX: ARPN) today elaborates on some addition...results and on those of other studies carried out, arpida is confident that intravenous iclaprim has compell...ts related to QTc elevation were reported. About arpida Ltd. ...

Arpida Invited to Present Data on Iclaprim at Scientific Conference

...CH, Switzerland, April 9 /PRNewswire-FirstCall/ -- arpida Ltd. (SWX: ARPN) announced today that a total of 1... discuss the latest developments in their field. arpida will be presenting additional efficacy and safety ...ence website starting today, 9 April 2008. About arpida Ltd. ...

Arpida adds novel antibiotic AR-2474 to its preclinical pipeline

...ion REINACH / BASEL, Switzerland, 8 March 2007 - arpida Ltd. (SWX: ARPN) today announced positive results ...mupirocin. Dr. Sergio Lociuro, Head of Research at arpida Ltd. commented, "AR-2474 originates from our own r...nds - For further information please contact: arpida Dr Khalid Islam, President and CEO Harry Tel: + 41...

Arpida Announces Promising Results of "First-In-Man" Studies With AR-709

...tzerland, March 29, 2007 /PRNewswire-FirstCall/ -- arpida Ltd. today announced promising results of "first-i...osing. Dr Sergio Lociuro, Head of Research of arpida Ltd. commented "I am very pleased with the results...ection both intravenously and by the oral route. arpida is completing the appropriate studies in order to ...

Arpida in Biological News

Phase III data show efficacy/safety of iclaprim in patients with complicated skin infections

... Reinach, Switzerland, 26 October 2008 arpida (SWX: ARPN) today presented the combined results from two pivotal Phase III clinical trials at the 48th Interscience Conference on Antimicrobial Agent...

Arpida in Biological Technology

Leadership Change to Enable Arpida to Become a Fully Integrated Pharmaceutical Company

REINACH, Switzerland, April 25 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that Dr Jurgen Raths will succeed Dr Khalid Islam as Chief Executive Officer. Dr Jurgen Raths commands extensive knowledge in the commercialisation of drugs for the treatment of severe infections i...

Arpida Annual General Meeting of Shareholders Approves All Board Proposals

... REINACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- The Annual General Meeting of arpida Ltd (SIX: ARPN) has approved the proposals that were put forward by the Board of Directors. A total of 90 shareholders were present at the meet...

Arpida to Discuss Strategy With Shareholders

...NACH, Switzerland, May 7 /PRNewswire-FirstCall/ -- arpida Ltd. (SIX: ARPN) will today discuss potential stra...gative FDA opinion regarding intravenous iclaprim, arpida has initiated a thorough analysis with the aim to ... by international experts in this field. As arpida lacks both the time and the money to complete this...

Board Reviews Strategic Options to Present to Shareholders at Shareholders' Meeting

...ch 17 /PRNewswire-FirstCall/ -- In their press release of 25 February 2009, arpida communicated that the Board of Directors was in the process of reviewing al...ompany as a whole less than the sum of its assets. It will therefore invite arpida shareholders to select their preferred strategic option at the shareholders...

Arpida Announces Full Year 2008 Financial Results

...Switzerland, February 25 /PRNewswire-FirstCall/ -- arpida Ltd (SIX: ARPN) announced today its financial resu...roceeds from the share issue of April 2008. arpida has adjusted the assumptions regarding the TLT-pro... Statutory Accounts Since inception, arpida has chosen to capitalise research and development ...

FDA Issues Complete Response Letter for Iclaprim

... Switzerland, January 19 /PRNewswire-FirstCall/ -- arpida Ltd. (SWX: ARPN) announces today that it has recei...ated safety data and labelling information. arpida today also announces that the restructuring that w...for re-election at the next shareholders' meeting. arpida wishes to thank both Board members for their valua...

Arpida to Restructure and Focus on Key Projects

...d a social plan will be presented in time. arpida will now thoroughly analyse the situation with ext...tially life threatening infections." About arpida Ltd. arpida (SWX: ARPN) is a biopharmaceutical company headqua...

Arpida's iclaprim MAA Accepted for Review by EMEA

..., Switzerland, August 21 /PRNewswire-FirstCall/ -- arpida Ltd. (SWX: ARPN) today announced that the European...sation Application (MAA) for intravenous iclaprim. arpida is seeking approval of intravenous iclaprim in the...h cSSTI. Dr Paul Hadvary, Head of Development of arpida Ltd., commented: "Iclaprim is under regulatory rev...

Arpida Reports Interim Results for Six Months to 30 June 2008

...cial Operations REINACH, Switzerland, August 20 /PRNewswire-FirstCall/ -- arpida Ltd (SWX: ARPN) announced today its financial results for the six months en... in Phase III trial with TLT approaches 50% - Leadership change to enable arpida to become a fully integrated pharmaceutical company - Raised CHF 19.6 mi...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...INC. (TSE: QLTI) SINCLAIR PHARMA PLC (London Main Market, U.K.: SPH) Add ANGES MG INC (Tokyo SE: 4563) APP PHARMACEUTICALS INC (NASDAQ: APPX ) arpida AG (SWX, Switzerland: ARPN) BTG (London Main Market, U.K.: BGC) CYTOS BIOTECH AG (SWX, Switzerland: CYTN) GENMAB AS (OMX Nordic Exchange Copenhagen...